Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Beam Therapeutics Inc.BEAM · Entity 4227 | Chief Medical Officer | July 27, 2026 | July 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Beam Therapeutics Inc.
Report date July 27, 2026 · Filed July 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 85,696 |
Reported balance
After 2026-07-27 transaction · row 1
1 source rowRow 1 · 2026-07-27 · Sale · Disposed 16,667 · Balance 85,696 F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 27, 2026 Filed Jul 29, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 16,667 | $25.74 | $429,036.91 |
DisclosureSEC source: 0001193125-26-323640 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,696 F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 27, 2026. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $25.32 to $26.05, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 373 | $34.73 | $12,954.29 |
DisclosureSEC source: 0001193125-26-294478 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,363 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. Read SEC document |
| April 01, 2026 Filed Apr 6, 2026 21:44 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 6,700 | $24.58 | $164,686.00 |
DisclosureSEC source: 0001193125-26-144080 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 102,735 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · balance_after: Includes 183 and 138 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2025 and March 31, 2026, respectively. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 21:16 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 31,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-140515 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 109,114 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 31, 2026 Filed Feb 2, 2026 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 88,500 | $0.00 Strike: $27.62 | $0.00 |
DisclosureSEC source: 0001193125-26-033598 · ownership.xml · derivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 88,500 Underlying: Common Stock · 88,500 shares Expires 2036-01-31 F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:11 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-002422 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 77,364 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| July 03, 2025 Filed Jul 3, 2025 21:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 876 | $20.12 | $17,625.12 |
DisclosureSEC source: 0000950170-25-094002 · ownership.xml · nonDerivative · entry 2 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,864 F3 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. Read SEC document |
| July 01, 2025 Filed Jul 3, 2025 21:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 374 | $16.94 | $6,336.42 |
DisclosureSEC source: 0000950170-25-094002 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,740 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · balance_after: Includes 372 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2024. Read SEC document |
| April 02, 2025 Filed Apr 4, 2025 01:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 20,997 | $17.73 | $372,293.61 |
DisclosureSEC source: 0000950170-25-050852 · ownership.xml · nonDerivative · entry 2 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,742 F3 · kind: The shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 7, 2024. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.20 to $18.12, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission , upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2025 Filed Apr 4, 2025 01:50 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 9,566 | $18.35 | $175,541.84 |
DisclosureSEC source: 0000950170-25-050852 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,739 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022, March 31, 2023 and March 31, 2024. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $17.76 to $18.38, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2025 Filed Apr 2, 2025 23:18 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-049765 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,305 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
| January 31, 2025 Filed Feb 3, 2025 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $25.92 | $0.00 |
DisclosureSEC source: 0000950170-25-012305 · ownership.xml · derivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2035-01-31 F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date. Read SEC document |
| July 02, 2024 Filed Jul 3, 2024 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 748 | $22.95 | $17,166.60 |
DisclosureSEC source: 0000950170-24-081492 · ownership.xml · nonDerivative · entry 2 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,805 F3 · kind: These shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. Read SEC document |
| July 01, 2024 Filed Jul 3, 2024 20:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 502 | $23.76 | $11,927.52 |
DisclosureSEC source: 0000950170-24-081492 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,553 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · balance_after: This reflects a correction to the previously reported amount of securities beneficially owned. Prior to the reported transaction, the Reporting Person beneficially owned 70,055 shares of common stock, not 70,060 shares. Read SEC document |
| April 02, 2024 Filed Apr 3, 2024 23:43 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 16,530 | $30.54 | $504,851.00 |
DisclosureSEC source: 0000950170-24-041441 · ownership.xml · nonDerivative · entry 2 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,060 F3 · kind: The shares of common stock were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $30.24 to $31.00, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 01, 2024 Filed Apr 3, 2024 23:43 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 7,157 | $32.13 | $229,954.41 |
DisclosureSEC source: 0000950170-24-041441 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 86,590 F1 · kind: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan on each of March 31, 2021, March 31, 2022 and March 31, 2023. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $32.10 to $32.17, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 31, 2024 Filed Apr 2, 2024 20:10 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-040152 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,747 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. F2 · balance_after: Includes 363 shares and 415 shares acquired by the Reporting Person under the BEAM Amended and Restated 2019 Employee Stock Purchase Plan on September 30, 2023 and March 31, 2024, respectively. Read SEC document |
| January 31, 2024 Filed Feb 2, 2024 21:05 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantStock Option (Right to Buy) · Derivative | 55,000 | $24.40 Strike: $24.40 | $1,342,000.00 |
DisclosureSEC source: 0000950170-24-010478 · ownership.xml · derivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2034-01-31 F1 · derivative.exercise_date: This stock option vests in equal monthly installments each month following the date of grant for the subsequent 48 months, subject to the Reporting Person's continued service with Beam Therapeutics Inc. through each vesting date. Read SEC document |
| October 30, 2023 Filed Nov 1, 2023 20:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 3,448 | $18.70 | $64,477.60 |
DisclosureSEC source: 0000950170-23-057499 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,469 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 29, 2023. Read SEC document |
| July 10, 2023 Filed Aug 9, 2023 20:08 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 391 | $30.48 | $11,917.68 |
DisclosureSEC source: 0000950170-23-040574 · ownership.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,917 F1 · shares: These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on June 30, 2022. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 00:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 1,161 | $29.09 | $33,776.51 |
DisclosureSEC source: 0000899243-23-010816 · doc4.xml · nonDerivative · entry 3 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 69,308 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $28.77 to $29.10, inclusive. The Reporting Person undertakes to provide to BEAM, any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 04, 2023 Filed Apr 6, 2023 00:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 10,493 | $29.77 | $312,338.84 |
DisclosureSEC source: 0000899243-23-010816 · doc4.xml · nonDerivative · entry 2 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 70,469 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $29.505 to $30.28, inclusive. The Reporting Person undertakes to provide to Beam Therapeutics Inc. ("BEAM"), any security holder of BEAM or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 00:30 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | SaleCommon Stock | 4,445 | $30.31 | $134,727.95 |
DisclosureSEC source: 0000899243-23-010816 · doc4.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,962 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person prior to February 27, 2023. F2 · balance_after: Includes 278 shares acquired by the Reporting Person under the Beam Therapeutics Inc. Amended and Restated 2019 Employee Stock Purchase Plan on March 31, 2023. Read SEC document |
| March 31, 2023 Filed Mar 31, 2023 23:47 UTC | Beam Therapeutics Inc. BEAM · Entity 4227 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-010134 · doc4.xml · nonDerivative · entry 1 Simon Amy · CIK 0001963879 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,129 F1 · shares: Represents restricted stock units ("RSUs") granted to the Reporting Person under the Beam Therapeutics Inc. ("BEAM") 2019 Equity Incentive Plan. Each RSU represents the contingent right to receive one share of BEAM's common stock. The RSUs vest in four substantially equal annual installments on each of the first four anniversaries of the date of grant, subject to the Reporting Person's continued service with BEAM through each vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.